More than 100 healthcare professionals from 41 hospitals and 10 countries rallied to share their experiences of the Aeson® artificial heart PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT ...

PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for ...

The retrospective analysis on 10 patients shows a 90% survival rate at 6 months, suggesting Aeson® as a therapeutic solution for these patients at risk of death in the short term. PARIS--(BUSINESS ...

(Reuters) -French artificial heart maker Carmat expects to break-even in 2027, it said on Monday, as it gradually resumes implants and faces strong demand in Europe ahead of its commercial launch in ...

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular ...

PARIS, Oct 23 (Reuters) - Carmat ALCAR.PA, the artificial heart maker which this month got a 7 million euros ($7.40 million) lifeline to survive an imminent cash crunch, on Monday announced solid ...

PARIS, Jan 4 (Reuters) - French healthcare and medical technology company CARMAT ALCAR.PA said on Wednesday that its Aeson artificial heart product would be implemented within the framework of a ...

Add Yahoo as a preferred source to see more of our stories on Google. An artificial heart manufactured by French firm Carmat is seen during the company's news conference in Paris PARIS (Reuters) ...

Carmat SA recently reported a software update for its bioprosthetic total artificial heart Aeson device that will significantly improve its safety profile. In the past, the company had to suspend ...

The forum brought together more than 100 European leaders in cardiology (cardiologists, surgeons, anaesthetists, intensivists, nurses, specialized distributors, etc ...

PARIS, Oct 23 (Reuters) - French artificial heart maker Carmat (ALCAR.PA), opens new tab said on Monday it had implanted seven of its Aeson devices as part of a clinical study in Paris, sending its ...